The estimated Net Worth of Linda Bain is at least $127 Tausend dollars as of 19 January 2023. Ms. Bain owns over 5,000 units of Arvinas Inc stock worth over $124,450 and over the last 11 years she sold ARVN stock worth over $2,280. In addition, she makes $0 as Director at Arvinas Inc.
Linda has made over 9 trades of the Arvinas Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently she sold 13,412 units of ARVN stock worth $2,280 on 28 March 2023.
The largest trade she's ever made was exercising 15,226 units of Arvinas Inc stock on 16 August 2022 worth over $378,975. On average, Linda trades about 2,411 units every 161 days since 2013. As of 19 January 2023 she still owns at least 5,000 units of Arvinas Inc stock.
You can see the complete history of Ms. Bain stock trades at the bottom of the page.
Linda C. Bain CPA serves as Director of the Company. Ms. Bain, who is currently the Chief Financial Officer of Codiak BioSciences, Inc., is an experienced business and financial leader with a strong track record of driving results, accelerating growth, and building shareholder value. Ms. Bain is an accomplished executive with extensive experience influencing strategy and leading the finances and operations of biotechnology and pharmaceutical companies. Prior to joining Codiak, Ms. Bain served as Chief Financial Officer of Avalanche Biotechnologies, where she led a successful initial public offering (IPO) and follow-on financing. Additionally, she served as Vice President of Finance, Business Operations, and Treasurer, as well as Chief Accounting Officer, at bluebird bio, where she led a successful Series D financing and IPO. Prior to bluebird bio, Ms. Bain held senior roles at Genzyme Corporation and was Vice President of Finance, Global Manufacturing and Operations, and Vice President of Finance, Genzyme Genetics. Earlier in her career she held senior roles at Fidelity Investments, AstraZeneca, and Deloitte & Touche. Ms. Bain is a Certified Public Accountant and earned a Bachelor of Science in Accounting and Business Administration and an Honors degree in Accounting and Business Administration from the University of the Free State, Bloemfontein South Africa.
Linda Bain is 46, she's been the Director of Arvinas Inc since 2020. There are 16 older and 2 younger executives at Arvinas Inc. The oldest executive at Arvinas Inc is Laurie Smaldone Alsup, 66, who is the Independent Director.
Linda's mailing address filed with the SEC is C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN, CT, 06511.
Over the last 6 years, insiders at Arvinas Inc have traded over $123,187,141 worth of Arvinas Inc stock and bought 3,567,290 units worth $69,124,444 . The most active insiders traders include Capital Management, L.P.Ra ..., Liam Ratcliffe und Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of $1,884,820. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth $244,472.
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
Arvinas Inc executives and other stock owners filed with the SEC include: